VentureMed Group names new president and chief executive officer
6 February 2019 -

VentureMed Group Inc, a privately-held medical device company that develops and markets the FLEX Vessel Prep System to treat peripheral arterial disease and stenoses of arteriovenous fistulas and grafts, announced yesterday that it has named J Robert Paulson, Jr as its new president and chief executive officer, and a member of the company's board of directors, effective 1 January 2019.

Paulson joins the company from NxThera, where he served as president, CEO and board director from 2009 until the company's acquisition by Boston Scientific in 2018. He previously served as president, CEO and board director of Restore Medical. He was CFO and VP of global marketing for Endocardial Solutions. Previously, he served as Sr VP/GM of the cochlear implant business at Advanced Bionics and served in several general management, corporate strategy and corporate development leadership roles at Medtronic.

Gary Smith, the Company's CEO since 2014, will continue to serve as a member of the leadership team.

Alexander Schmitz, a partner at Endeavour Vision Ltd, and a member of the company's board of directors, said, 'Bob brings tremendous knowledge and experience to the VentureMed Group, together with a strong track record of building successful teams and commercialising compelling new medical technologies. We look forward to Bob's contributions and leadership during this next phase of the Company's growth. On behalf of the board of directors, I would like to thank Gary for his significant contributions, which have created a solid foundation for the future success of the VentureMed Group.'